- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01062776
Kinetic Method to Detect Dehydration
August 18, 2010 updated by: Sodertalje Hospital
New Method to Detect Dehydration
- The distribution and elimination of infusion fluids can be studied by volume kinetics, a mathematical method based on serial analysis of the blood hemoglobin concentration.
- The hypothesis of the present study is that the elimination of infused fluid is retarded in the presence of dehydration, and that volume kinetics would therefore be capable of detecting dehydration in human subjects.
- We induce dehydration by injection graded doses of furosemide (a diuretic drug) in healthy volunteers and the kinetics of an infusion of crystalloid fluid is compared to when the same volunteer receives the same fluid without being in a dehydrated state.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
- Fifteen healthy male volunteers are subjected to 4 experiments. They drink 800 ml of water at 6:00 AM to make sure they are not dehydrated when the experiments begin.
- On two occasions the volunteer receives, at 9:00 AM, an intravenous infusion of acetated Ringer´s solution being either 5 ml/kg or 10 ml/kg, over 15 min. The blood hemoglobin concentration is measured during 16 occasions during 120 min by invasive blood sampling and also non-invasively by a pulse oximeter (Masimo´s Radical 7).
- On two other occasions, the infusions are preceded for 2 hours of deliberate dehydration. Doses of furosemide 5 mg are repeated 3-4 times with the goal of creating dehydration amounting to approximately 2 liters of fluid. Excreted urine is collected and the volume measured.
- The kinetics of each infusion is calculated by volume kinetics, and the data compared pairwise from the experiments with and those without dehydration.
- The accuracy and precision of the non-invasive monitoring of Hgb can be determined.
- The study is ended with that the Hgb response between the lying and sitting position is compared and with that the fluid balance is restored by ingestion of water.
- Experiments are performed in the Department of Intensive Care at Linköping University Hospital, Sweden.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Linköping, Sweden, 58185
- Department of Intensive Care, University hospital, Linköping, Sweden
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 30 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy male.
Exclusion Criteria:
- Disease for which daily medication is required.
- Poor peripheral perfusion; defined as a perfusion index, as measured by Masimo´s Radical 7, of 2 or less.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: 5 ml/kg of fluid, no dehydration
Volunteers receive an intravenous infusion of acetated Ringers solution over 15 min without preceding deliberate dehydration with furosemide.
|
No dehydration is induced
Other Names:
|
|
Placebo Comparator: 10 ml/kg of fluid, no dehydration
Volunteers receive an intravenous infusion of acetated Ringers solution over 15 min without preceding deliberate dehydration with furosemide.
|
No dehydration is induced
Other Names:
|
|
Experimental: 5 ml/kg of fluid, dehydration
Volunteers receive an intravenous infusion of 5 ml/kg acetated Ringers solution over 15 min after being dehydrated with furosemide.
|
Furosemide 5 mg is given intravenously over 2 hours until approximately 2 liters of body fluid is lost.
Other Names:
|
|
Experimental: 10 ml/kg of fluid, dehydration
Volunteers receive an intravenous infusion of 10 ml/kg acetated Ringers solution over 15 min after being dehydrated with furosemide.
|
Furosemide 5 mg is given intravenously over 2 hours until approximately 2 liters of body fluid is lost.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
As determined by volume kinetics, a healthy human male eliminates infused crystalloid fluid more slowly when being in the dehydrated state as compared to when being normohydrated.
Time Frame: December 2010
|
December 2010
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The volume kinetics of an infusion fluid can/can not be measured as accurately by non-invasive monitoring as by invasive monitoring of the blood hemoglobin concentration
Time Frame: May 2010 (preliminary analysis)
|
May 2010 (preliminary analysis)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Robert G Hahn, MD, PhD, Södertälje Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2009
Primary Completion (Actual)
May 1, 2010
Study Completion (Actual)
May 1, 2010
Study Registration Dates
First Submitted
February 3, 2010
First Submitted That Met QC Criteria
February 3, 2010
First Posted (Estimate)
February 4, 2010
Study Record Updates
Last Update Posted (Estimate)
August 19, 2010
Last Update Submitted That Met QC Criteria
August 18, 2010
Last Verified
November 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- M114-09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dehydration
-
United States Army Research Institute of Environmental...CompletedDehydration Hypertonic | Isotonic Dehydration
-
University of HartfordArizona State University; Kraft Heinz CompanyCompletedDehydration in Children | Dehydration Following Exertion (Disorder)United States
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...UnknownAged | Dehydration HypertonicItaly
-
University of DelawareNational Heart, Lung, and Blood Institute (NHLBI); National Institute of General...Completed
-
Rhode Island HospitalInternational Centre for Diarrhoeal Disease Research, Bangladesh; Fogarty International...Completed
-
Wayne State UniversityUniversity of ChicagoUnknown
-
University College, LondonUniversity of Portsmouth; University of WollongongUnknownDehydration HypertonicUnited Kingdom
-
University of North Carolina, GreensboroNot yet recruitingWater Stress | Body Water DehydrationUnited States
-
Arizona State UniversityKraft Heinz CompanyCompleted
-
Children's Hospital Los Angeles410 Medical; Atlanta Pediatric Device ConsortiumCompletedDehydration in Children | DehydrationUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of